{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-005097","form_type":"8-K/A","ticker":"OCEA","cik":"0001869974","company_name":"Ocean Biomedical, Inc.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.284928+00:00","generated_at":"2026-06-19T12:09:50.498969+00:00","sec_items":["1.01","2.01","5.02","3.02","9.01","4.01","2.03","3.03","5.01","5.03","5.05","5.06"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Ocean Biomedical files amendment to add exhibits to business combination 8-K; no new operational news","bullets":["Amendment No. 1 to 8-K filed solely to attach exhibits omitted from original Feb. 14, 2023 filing due to EDGAR server limits.","Exhibits include business combination agreement, lock-up agreements, non-competition agreement, and indemnification agreements.","No changes to the previously reported business combination terms or post-Closing capital structure.","Pro forma financial information and comparative per share data referenced as Exhibit 99.1 but not provided in this text."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-005097","json":"https://secwatch.observer/filing/0001493152-23-005097.json","markdown":"https://secwatch.observer/filing/0001493152-23-005097.md","text":"https://secwatch.observer/filing/0001493152-23-005097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T12:09:50.498969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03343405c4","claim":"Michelle Berrey was appointed as Class I Director at Ocean Biomedical, Inc..","evidence_excerpt":"Michelle Berrey, M.D., MPH (1)(2)(3) 56 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"2b721cefa2","claim":"Dr. Jack A. Elias was appointed as Class II Director at Ocean Biomedical, Inc..","evidence_excerpt":"Dr. Jack A. Elias, M.D. 71 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"4caf1bc728","claim":"William Owens was appointed as Class I Director at Ocean Biomedical, Inc..","evidence_excerpt":"William Owens (1)(3) 72 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"523988968a","claim":"Suren Ajjarapu resigned as Chairman of the Board at Ocean Biomedical, Inc..","evidence_excerpt":"Suren Ajjarapu served as Aesther’s Chairman and Chief Executive Officer from Aesther’s inception in June 2021 until the Closing of the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"595d844858","claim":"Suren Ajjarapu resigned as Chief Executive Officer at Ocean Biomedical, Inc..","evidence_excerpt":"Suren Ajjarapu served as Aesther’s Chairman and Chief Executive Officer from Aesther’s inception in June 2021 until the Closing of the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"5e4fe0362e","claim":"Martin D. Angle was appointed as Class II Director at Ocean Biomedical, Inc..","evidence_excerpt":"Martin D. Angle (1)(2) 72 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"6f67e1361e","claim":"Dr. Chirinjeev Kathuria was appointed as Founder, Executive Chairman, Class III Director at Ocean Biomedical, Inc..","evidence_excerpt":"Dr. Chirinjeev Kathuria, M.D. 58 Founder, Executive Chairman, Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Founder, Executive Chairman, Class III Director"}],"fact_type":"executive_change"},{"claim_id":"74c450c085","claim":"Michael Peterson was appointed as Class II Director at Ocean Biomedical, Inc..","evidence_excerpt":"Michael Peterson 60 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"7d9fdd3411","claim":"Daniel Behr was appointed as Executive Vice President and Head of External Innovation and Academic Partnerships at Ocean Biomedical, Inc..","evidence_excerpt":"Daniel Behr, MBA 64 Executive Vice President and Head of External Innovation and Academic Partnerships","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Head of External Innovation and Academic Partnerships"}],"fact_type":"executive_change"},{"claim_id":"9e217c30bf","claim":"Jerome Ringo was appointed as Class I Director at Ocean Biomedical, Inc..","evidence_excerpt":"Jerome Ringo (2)(3) 67 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"a0987e047f","claim":"Inderjote Kathuria was appointed as Chief Strategy Officer at Ocean Biomedical, Inc..","evidence_excerpt":"Inderjote Kathuria, M.D. 56 Chief Strategy Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Strategy Officer"}],"fact_type":"executive_change"},{"claim_id":"b3c4549df8","claim":"Elizabeth Ng was appointed as Chief Executive Officer and Class III Director at Ocean Biomedical, Inc..","evidence_excerpt":"Elizabeth Ng, MBA 66 Chief Executive Officer and Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Class III Director"}],"fact_type":"executive_change"},{"claim_id":"d0ac6c40ef","claim":"Jonathan Kurtis was appointed as Class I Director at Ocean Biomedical, Inc..","evidence_excerpt":"Jonathan Kurtis, M.D., Ph.D. 55 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"dff853b0e6","claim":"Gurinder Kalra was appointed as Chief Financial Officer at Ocean Biomedical, Inc..","evidence_excerpt":"Gurinder Kalra, MBA 57 Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"eb31652d2c","claim":"Suren Ajjarapu was appointed as Class III Director at Ocean Biomedical, Inc..","evidence_excerpt":"Suren Ajjarapu 52 Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"ec56fa3ace","claim":"Robert Sweeney was appointed as Chief Accounting Officer at Ocean Biomedical, Inc..","evidence_excerpt":"Robert Sweeney 57 Chief Accounting Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"61dc6cf0158e43d8aca34fb3461c239b0018c095","claim":"Ocean Biomedical, Inc.: Filed Amended Certificate with the Secretary of State of Delaware.","evidence_excerpt":"On the Closing Date, Aesther filed its Amended Certificate with the Secretary of State of the State of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"98fd36e855de90ac6820ef370b65202b2249b25a","claim":"Ocean Biomedical, Inc.: Expects Board to adopt and approve a new Code of Business Conduct and Ethics.","evidence_excerpt":"the Company expects the Board to adopt and approve a new Code of Business Conduct and Ethics applicable to all employees, officers, and directors of the Company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.7,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"af9058bf44b94419780007cc09bad1342036cd6a","claim":"Ocean Biomedical, Inc.: Company ceased to be a shell company as a result of the Business Combination.","evidence_excerpt":"As a result of the Business Combination, the Company ceased to be a shell company as of the Closing.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"}],"fact_type":"governance_change"},{"claim_id":"c1a6b5272d49036280d5034d802bfe2e5050f376","claim":"Ocean Biomedical, Inc.: Amended and restated bylaws for public operating company including changes to provisions relating to special meetings, proxy solicitation, director vacancies, Board committees and stockholder proposals.","evidence_excerpt":"upon the Closing, pursuant to the terms of the Business Combination Agreement, Aesther amended and restated its bylaws to make certain changes that the Board deems appropriate for a public operating company, including, but not limited to, changes to provisions relating to special meetings in lieu of annual meetings, proxy solicitation and voting, director vacancies and removals, Board committees and stockholder proposals.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"c8164bcbdba5a187fe6de3a35e990a140ab0eb10","claim":"Ocean Biomedical, Inc. underwent a change of control involving Aesther Healthcare Acquisition Corp. for $233,554,320 (closed 2023-02-14).","evidence_excerpt":"as of immediately prior to the Closing approximately 23,355,432 shares of the Company’s Class A common stock (with a per-share value of $10.00) with an aggregate value equal to $233,554,320, as adjusted as required by the Business Combination Agreement to take into account net working capital, closing net debt and Legacy Ocean’s transaction expenses, in exchange for","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223005097/0001493152-23-005097-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Aesther Healthcare Acquisition Corp."},{"label":"Consideration","value":"$233,554,320"},{"label":"Closing","value":"2023-02-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}